Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) traded down 9.3% on Tuesday . The company traded as low as $5.72 and last traded at $5.77. 679,137 shares traded hands during trading, a decline of 80% from the average session volume of 3,473,137 shares. The stock had previously closed at $6.36. Analyst Ratings Changes […]
Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Fate Therapeutics (NASDAQ:FATE – Get Rating) will release its earnings data after the market closes on Wednesday, May 3rd. Analysts expect Fate Therapeutics to post earnings of ($0.55) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. Fate Therapeutics (NASDAQ:FATE – Get […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating)’s share price dropped 9.3% on Tuesday . The stock traded as low as $5.72 and last traded at $5.77. Approximately 679,137 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 3,473,137 shares. The stock had previously closed at $6.36. Analyst Upgrades […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and Poseida Therapeutics (NASDAQ:PSTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Institutional and Insider Ownership 46.7% of Poseida Therapeutics shares […]